Onkologie. 2008:2(4):229-232

THE POSSIBILITY OF LABORATORY TESTING FOR ONKOLOGICAL PATIENTS

Mirka Nekulová
Masarykův onkologický ústav, Brno

The examinations of tumor markers and  the other laboratory parameters in serum, plama or tissue of patients with malignant diagnoses, their validity (sensitivity and specificity), biological half-time,  timing and applications in terms of recommendations of international working groups for tumor markers  are summarized  in the view of clinical oncology. Also individual characteristics for  tumor markers and their accurate  indications are presented  as well as perspective metods for future.

Keywords: Key words: tumor markers, biological half-time, timing, indications, validity.

Published: December 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nekulová M. THE POSSIBILITY OF LABORATORY TESTING FOR ONKOLOGICAL PATIENTS. Onkologie. 2008;2(4):229-232.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11251019&dopt=Abstract (ASCO, 2000).
    2. http://www.clinchem.org/cgi/content/full/48/8/1151 (Sturgeon, 2002).
    3. Duffy MJ, Dalen A van, Haglund C, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer, 2003; 39(6): 718-727. Go to original source... Go to PubMed...
    4. Adam Z, Vorlíček J, Koptíková J, et al. Obecná onkologie a podpůrná léčba, Praha: Grada, 2003; 787 s.
    5. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer, 1999 Sep 1; 86(5): 858-865. Go to original source...
    6. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest, 2005; 23(4): 338-351. Go to original source... Go to PubMed...
    7. Bast RC Jr., Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol, 2001; 19(6): 1865-1878. Erratum in: J Clin Oncol, 2001; 19(21): 4185-4188. J Clin Oncol, 2002; 20(8): 2213. Go to original source... Go to PubMed...
    8. Molina R, Barak V, van Dalen A, et al. Tumor markers in breast cancer - Europ. Group on Tumor Markers recommendations. Tumour Biol., 2005 Nov-Dec; 26(6): 281-293. Go to original source... Go to PubMed...
    9. Hoffman BR, Diamandis EP. Recent advances in cancer biomarkers. Clin Biochem., 2004 Jul; 37(7): 503-504. Go to original source... Go to PubMed...
    10. Marks V. False-positive immunoassay results: a multicenter survey of erroneous immunoassay results from assays of 74 analytes in 10 donors from 66 laboratories in seven countries. Clin Chem., 2002 Nov; 48(11): 2008-2016. Go to original source...
    11. Hoefner DM. Serum tumor markers. Part I: Clinical utility. / MLO Med Lab Obs., 2005; 37(12): 20, 22-24.
    12. Kaneda A, Feinberg APOD. Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res., 2005 Dec 15; 65(24): 11236-11240. Go to original source... Go to PubMed...
    13. Michalová K, Zemanová Z. Klasická a molekulární cytogenetika v klinické praxi, Klin.Biochem.Metab., 2005; 13(34)No 2: 63-67.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.